Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety

Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (RCC). Although these TKIs are associated with similar survival outcomes, some differences have been reported in their safety profiles. In this work, traditional toxicological...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaro, Filipa, Pisoeiro, Carolina, Valente, Maria João, Bastos, Maria de Lourdes, Guedes de Pinho, Paula, Carvalho, Márcia, Pinto, Joana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456255/
https://www.ncbi.nlm.nih.gov/pubmed/36077297
http://dx.doi.org/10.3390/ijms23179898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456255/
https://www.ncbi.nlm.nih.gov/pubmed/36077297
http://dx.doi.org/10.3390/ijms23179898

Ejemplares similares